Rutgers New Jersey Medical School

PROBLEM/CONDITION: Autism spectrum disorder (ASD). PERIOD COVERED: 2016. DESCRIPTION OF SYSTEM: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance program that provides estimates of the prevalence of ASD among children aged 8 years whose parents or guardians live in 11 ADDM Network sites in the United States (Arizona, Arkansas, Colorado, Georgia, Maryland, Minnesota, Missouri, New Jersey, North Carolina, Tennessee, and Wisconsin). Surveillance is conducted in two phases. The first phase involves review and abstraction of comprehensive evaluations that were completed by medical and educational service providers in the community. In the second phase, experienced clinicians who systematically review all abstracted information determine ASD case status. The case definition is based on ASD criteria described in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. RESULTS: For 2016, across all 11 sites, ASD prevalence was 18.5 per 1,000 (one in 54) children aged 8 years, and ASD was 4.3 times as prevalent among boys as among girls. ASD prevalence varied by site, ranging from 13.1 (Colorado) to 31.4 (New Jersey). Prevalence estimates were approximately identical for non-Hispanic white (white), non-Hispanic black (black), and Asian/Pacific Islander children (18.5, 18.3, and 17.9, respectively) but lower for Hispanic children (15.4). Among children with ASD for whom data on intellectual or cognitive functioning were available, 33% were classified as having intellectual disability (intelligence quotient [IQ] ≤70); this percentage was higher among girls than boys (39% versus 32%) and among black and Hispanic than white children (47%, 36%, and 27%, respectively) [corrected]. Black children with ASD were less likely to have a first evaluation by age 36 months than were white children with ASD (40% versus 45%). The overall median age at earliest known ASD diagnosis (51 months) was similar by sex and racial and ethnic groups; however, black children with IQ ≤70 had a later median age at ASD diagnosis than white children with IQ ≤70 (48 months versus 42 months). INTERPRETATION: The prevalence of ASD varied considerably across sites and was higher than previous estimates since 2014. Although no overall difference in ASD prevalence between black and white children aged 8 years was observed, the disparities for black children persisted in early evaluation and diagnosis of ASD. Hispanic children also continue to be identified as having ASD less frequently than white or black children. PUBLIC HEALTH ACTION: These findings highlight the variability in the evaluation and detection of ASD across communities and between sociodemographic groups. Continued efforts are needed for early and equitable identification of ASD and timely enrollment in services.

Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that incorporation of composite clinical measures of phenotypic age that capture differences in lifespan and healthspan may identify novel CpGs and facilitate the development of a more powerful epigenetic biomarker of aging. Using an innovative two-step process, we develop a new epigenetic biomarker of aging, DNAm PhenoAge, that strongly outperforms previous measures in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, healthspan, physical functioning, and Alzheimer's disease. While this biomarker was developed using data from whole blood, it correlates strongly with age in every tissue and cell tested. Based on an in-depth transcriptional analysis in sorted cells, we find that increased epigenetic, relative to chronological age, is associated with increased activation of pro-inflammatory and interferon pathways, and decreased activation of transcriptional/translational machinery, DNA damage response, and mitochondrial signatures. Overall, this single epigenetic biomarker of aging is able to capture risks for an array of diverse outcomes across multiple tissues and cells, and provide insight into important pathways in aging.

Although it is being successfully implemented for exploration of the genome, discovery science has eluded the functional neuroimaging community. The core challenge remains the development of common paradigms for interrogating the myriad functional systems in the brain without the constraints of a priori hypotheses. Resting-state functional MRI (R-fMRI) constitutes a candidate approach capable of addressing this challenge. Imaging the brain during rest reveals large-amplitude spontaneous low-frequency (<0.1 Hz) fluctuations in the fMRI signal that are temporally correlated across functionally related areas. Referred to as functional connectivity, these correlations yield detailed maps of complex neural systems, collectively constituting an individual's "functional connectome." Reproducibility across datasets and individuals suggests the functional connectome has a common architecture, yet each individual's functional connectome exhibits unique features, with stable, meaningful interindividual differences in connectivity patterns and strengths. Comprehensive mapping of the functional connectome, and its subsequent exploitation to discern genetic influences and brain-behavior relationships, will require multicenter collaborative datasets. Here we initiate this endeavor by gathering R-fMRI data from 1,414 volunteers collected independently at 35 international centers. We demonstrate a universal architecture of positive and negative functional connections, as well as consistent loci of inter-individual variability. Age and sex emerged as significant determinants. These results demonstrate that independent R-fMRI datasets can be aggregated and shared. High-throughput R-fMRI can provide quantitative phenotypes for molecular genetic studies and biomarkers of developmental and pathological processes in the brain. To initiate discovery science of brain function, the 1000 Functional Connectomes Project dataset is freely accessible at www.nitrc.org/projects/fcon_1000/.

Schizophrenia has a heritability of 60–80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies. A genome-wide association study including over 76,000 individuals with schizophrenia and over 243,000 control individuals identifies common variant associations at 287 genomic loci, and further fine-mapping analyses highlight the importance of genes involved in synaptic processes.

autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.

.Using large scale validation data from thousands of individuals, we demonstrate that DNAm GrimAge stands out among existing epigenetic clocks in terms of its predictive ability for time-to-death (Cox regression P=2.0E-75), time-to-coronary heart disease (Cox P=6.2E-24), time-to-cancer (P= 1.3E-12), its strong relationship with computed tomography data for fatty liver/excess visceral fat, and age-at-menopause (P=1.6E-12). AgeAccelGrim is strongly associated with a host of age-related conditions including comorbidity count (P=3.45E-17). Similarly, age-adjusted DNAm PAI-1 levels are associated with lifespan (P=5.4E-28), comorbidity count (P= 7.3E-56) and type 2 diabetes (P=2.0E-26). These DNAm-based biomarkers show the expected relationship with lifestyle factors including healthy diet and educational attainment.Overall, these epigenetic biomarkers are expected to find many applications including human anti-aging studies.

Problem/Condition: Autism spectrum disorder (ASD). Period Covered: 2020. Description of System: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance program that provides estimates of the prevalence of ASD among children aged 8 years. In 2020, there were 11 ADDM Network sites across the United States (Arizona, Arkansas, California, Georgia, Maryland, Minnesota, Missouri, New Jersey, Tennessee, Utah, and Wisconsin). To ascertain ASD among children aged 8 years, ADDM Network staff review and abstract developmental evaluations and records from community medical and educational service providers. A child met the case definition if their record documented 1) an ASD diagnostic statement in an evaluation, 2) a classification of ASD in special education, or 3) an ASD International Classification of Diseases (ICD) code. Results: For 2020, across all 11 ADDM sites, ASD prevalence per 1,000 children aged 8 years ranged from 23.1 in Maryland to 44.9 in California. The overall ASD prevalence was 27.6 per 1,000 (one in 36) children aged 8 years and was 3.8 times as prevalent among boys as among girls (43.0 versus 11.4). Overall, ASD prevalence was lower among non-Hispanic White children (24.3) and children of two or more races (22.9) than among non-Hispanic Black or African American (Black), Hispanic, and non-Hispanic Asian or Pacific Islander (A/PI) children (29.3, 31.6, and 33.4 respectively). ASD prevalence among non-Hispanic American Indian or Alaska Native (AI/AN) children (26.5) was similar to that of other racial and ethnic groups. ASD prevalence was associated with lower household income at three sites, with no association at the other sites.Across sites, the ASD prevalence per 1,000 children aged 8 years based exclusively on documented ASD diagnostic statements was 20.6 (range = 17.1 in Wisconsin to 35.4 in California). Of the 6,245 children who met the ASD case definition, 74.7% had a documented diagnostic statement of ASD, 65.2% had a documented ASD special education classification, 71.6% had a documented ASD ICD code, and 37.4% had all three types of ASD indicators. The median age of earliest known ASD diagnosis was 49 months and ranged from 36 months in California to 59 months in Minnesota.Among the 4,165 (66.7%) children with ASD with information on cognitive ability, 37.9% were classified as having an intellectual disability. Intellectual disability was present among 50.8% of Black, 41.5% of A/PI, 37.8% of two or more races, 34.9% of Hispanic, 34.8% of AI/AN, and 31.8% of White children with ASD. Overall, children with intellectual disability had earlier median ages of ASD diagnosis (43 months) than those without intellectual disability (53 months). Interpretation: For 2020, one in 36 children aged 8 years (approximately 4% of boys and 1% of girls) was estimated to have ASD. These estimates are higher than previous ADDM Network estimates during 2000-2018. For the first time among children aged 8 years, the prevalence of ASD was lower among White children than among other racial and ethnic groups, reversing the direction of racial and ethnic differences in ASD prevalence observed in the past. Black children with ASD were still more likely than White children with ASD to have a co-occurring intellectual disability. Public Health Action: The continued increase among children identified with ASD, particularly among non-White children and girls, highlights the need for enhanced infrastructure to provide equitable diagnostic, treatment, and support services for all children with ASD. Similar to previous reporting periods, findings varied considerably across network sites, indicating the need for additional research to understand the nature of such differences and potentially apply successful identification strategies across states.

The purpose of this new classification compendium is to republish the Orthopaedic Trauma Association's (OTA) classification. The OTA classification was originally published in a compendium of the Journal of Orthopaedic Trauma in 1996. It adopted The Comprehensive Classification of the Long Bones developed by Müller and colleagues and classified the remaining bones. In this compendium, the introductory chapter reviews new scientific information about classifying fractures that has been published in the last 11 years. The classification is presented in a revised format that is easier to follow. The OTA and AO classification will now have a unified alpha-numeric code eliminating the differences that have existed between the 2 codes. The code was significantly revised for the clavicle and scapula, foot and hand, and patella. Dislocations have been expanded on an anatomic basis and for most joints will be coded separately. This publication should stimulate new developments and interest in a unified language to code and classify fractures. Further improvements in classification will result in better patient care and clinical research.

This article represents the content of the booklet, International Standards for Neurological Classification of Spinal Cord Injury, revised 2011, published by the American Spinal Injury Association (ASIA). For further explanation of the clarifications and changes in this revision, see the accompanying article (Kirshblum S., et al. J Spinal Cord Med. 2011:doi 10.1179/107902611X13186000420242 The spinal cord is the major conduit through which motor and sensory information travels between the brain and body. The spinal cord contains longitudinally oriented spinal tracts (white matter) surrounding central areas (gray matter) where most spinal neuronal cell bodies are located. The gray matter is organized into segments comprising sensory and motor neurons. Axons from spinal sensory neurons enter and axons from motor neurons leave the spinal cord via segmental nerves or roots. In the cervical spine, there are 8 nerve roots. Cervical roots of C1-C7 are named according to the vertebra above which they exit (i.e. C1 exits above the C1 vertebra, just below the skull and C6 nerve roots pass between the C5 and C6 vertebrae) whereas C8 exists between the C7 and T1 vertebra; as there is no C8 vertebra. The C1 nerve root does not have a sensory component that is tested on the International Standards Examination. The thoracic spine has 12 distinct nerve roots and the lumbar spine consists of 5 distinct nerve roots that are each named accordingly as they exit below the level of the respective vertebrae. The sacrum consists of 5 embryonic sections that have fused into one bony structure with 5 distinct nerve roots that exit via the sacral foramina. The spinal cord itself ends at approximately the L1-2 vertebral level. The distal most part of the spinal cord is called the conus medullaris. The cauda equina is a cluster of paired (right and left) lumbosacral nerve roots that originate in the region of the conus medullaris and travel down through the thecal sac and exit via the intervertebral foramen below their respective vertebral levels. There may be 0, 1, or 2 coccygeal nerves but they do not have a role with the International Standards examination in accordance with the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). Each root receives sensory information from skin areas called dermatomes. Similarly each root innervates a group of muscles called a myotome. While a dermatome usually represents a discrete and contiguous skin area, most roots innervate more than one muscle, and most muscles are innervated by more than one root. Spinal cord injury (SCI) affects conduction of sensory and motor signals across the site(s) of lesion(s), as well as the autonomic nervous system. By systematically examining the dermatomes and myotomes, as described within this booklet, one can determine the cord segments affected by the SCI. From the International Standards examination several measures of neurological damage are generated, e.g., Sensory and Motor Levels (on right and left sides), NLI, Sensory Scores (Pin Prick and Light Touch), Motor Scores (upper and lower limb), and ZPP. This booklet also describes the ASIA (American Spinal Injury Association) Impairment Scale (AIS) to classify the severity (i.e. completeness) of injury. This booklet begins with basic definitions of common terms used herein. The section that follows describes the recommended International Standards examination, including both sensory and motor components. Subsequent sections cover sensory and motor scores, the AIS classification, and clinical syndromes associated with SCI. For ease of reference, a worksheet (Appendix 1) of the recommended examination is included, with a summary of steps used to classify the injury (Appendix 2). A full-size version for photocopying and use in patient records has been included as an enclosure and may also be downloaded from the ASIA website (www.asia-spinalinjury.org). Additional details regarding the examination and e-Learning training materials can also be obtained from the website15.

BACKGROUND: Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, particularly for the detection of drug-resistant forms and in patients with human immunodeficiency virus infection. Early detection is essential to reduce the death rate and interrupt transmission, but the complexity and infrastructure needs of sensitive methods limit their accessibility and effect. METHODS: We assessed the performance of Xpert MTB/RIF, an automated molecular test for Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF), with fully integrated sample processing in 1730 patients with suspected drug-sensitive or multidrug-resistant pulmonary tuberculosis. Eligible patients in Peru, Azerbaijan, South Africa, and India provided three sputum specimens each. Two specimens were processed with N-acetyl-L-cysteine and sodium hydroxide before microscopy, solid and liquid culture, and the MTB/RIF test, and one specimen was used for direct testing with microscopy and the MTB/RIF test. RESULTS: Among culture-positive patients, a single, direct MTB/RIF test identified 551 of 561 patients with smear-positive tuberculosis (98.2%) and 124 of 171 with smear-negative tuberculosis (72.5%). The test was specific in 604 of 609 patients without tuberculosis (99.2%). Among patients with smear-negative, culture-positive tuberculosis, the addition of a second MTB/RIF test increased sensitivity by 12.6 percentage points and a third by 5.1 percentage points, to a total of 90.2%. As compared with phenotypic drug-susceptibility testing, MTB/RIF testing correctly identified 200 of 205 patients (97.6%) with rifampin-resistant bacteria and 504 of 514 (98.1%) with rifampin-sensitive bacteria. Sequencing resolved all but two cases in favor of the MTB/RIF assay. CONCLUSIONS: The MTB/RIF test provided sensitive detection of tuberculosis and rifampin resistance directly from untreated sputum in less than 2 hours with minimal hands-on time. (Funded by the Foundation for Innovative New Diagnostics.)

Interferons (IFNs) are the most important cytokines in antiviral immune responses. "Natural IFN-producing cells" (IPCs) in human blood express CD4 and major histocompatibility complex class II proteins, but have not been isolated and further characterized because of their rarity, rapid apoptosis, and lack of lineage markers. Purified IPCs are here shown to be the CD4(+)CD11c- type 2 dendritic cell precursors (pDC2s), which produce 200 to 1000 times more IFN than other blood cells after microbial challenge. pDC2s are thus an effector cell type of the immune system, critical for antiviral and antitumor immune responses.

BACKGROUND: Recent randomized clinical trials have suggested that estrogen plus progestin does not confer cardiac protection and may increase the risk of coronary heart disease (CHD). In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI). METHODS: The WHI included a randomized primary-prevention trial of estrogen plus progestin in 16,608 postmenopausal women who were 50 to 79 years of age at base line. Participants were randomly assigned to receive conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The primary efficacy outcome of the trial was CHD (nonfatal myocardial infarction or death due to CHD). RESULTS: After a mean follow-up of 5.2 years (planned duration, 8.5 years), the data and safety monitoring board recommended terminating the estrogen-plus-progestin trial because the overall risks exceeded the benefits. Combined hormone therapy was associated with a hazard ratio for CHD of 1.24 (nominal 95 percent confidence interval, 1.00 to 1.54; 95 percent confidence interval after adjustment for sequential monitoring, 0.97 to 1.60). The elevation in risk was most apparent at one year (hazard ratio, 1.81 [95 percent confidence interval, 1.09 to 3.01]). Although higher base-line levels of low-density lipoprotein cholesterol were associated with an excess risk of CHD among women who received hormone therapy, higher base-line levels of C-reactive protein, other biomarkers, and other clinical characteristics did not significantly modify the treatment-related risk of CHD. CONCLUSIONS: Estrogen plus progestin does not confer cardiac protection and may increase the risk of CHD among generally healthy postmenopausal women, especially during the first year after the initiation of hormone use. This treatment should not be prescribed for the prevention of cardiovascular disease.

PROBLEM/CONDITION: Autism spectrum disorder (ASD). PERIOD COVERED: 2012. DESCRIPTION OF SYSTEM: The Autism and Developmental Disabilities Monitoring (ADDM) Network is an active surveillance system that provides estimates of the prevalence and characteristics of ASD among children aged 8 years whose parents or guardians reside in 11 ADDM Network sites in the United States (Arkansas, Arizona, Colorado, Georgia, Maryland, Missouri, New Jersey, North Carolina, South Carolina, Utah, and Wisconsin). Surveillance to determine ASD case status is conducted in two phases. The first phase consists of screening and abstracting comprehensive evaluations performed by professional service providers in the community. Data sources identified for record review are categorized as either 1) education source type, including developmental evaluations to determine eligibility for special education services or 2) health care source type, including diagnostic and developmental evaluations. The second phase involves the review of all abstracted evaluations by trained clinicians to determine ASD surveillance case status. A child meets the surveillance case definition for ASD if one or more comprehensive evaluations of that child completed by a qualified professional describes behaviors that are consistent with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnostic criteria for any of the following conditions: autistic disorder, pervasive developmental disorder-not otherwise specified (including atypical autism), or Asperger disorder. This report provides ASD prevalence estimates for children aged 8 years living in catchment areas of the ADDM Network sites in 2012, overall and stratified by sex, race/ethnicity, and the type of source records (education and health records versus health records only). In addition, this report describes the proportion of children with ASD with a score consistent with intellectual disability on a standardized intellectual ability test, the age at which the earliest known comprehensive evaluation was performed, the proportion of children with a previous ASD diagnosis, the specific type of ASD diagnosis, and any special education eligibility classification. RESULTS: For 2012, the combined estimated prevalence of ASD among the 11 ADDM Network sites was 14.5 per 1,000 (one in 69) children aged 8 years. Estimated prevalence was significantly higher among boys aged 8 years (23.4 per 1,000) than among girls aged 8 years (5.2 per 1,000). Estimated ASD prevalence was significantly higher among non-Hispanic white children aged 8 years (15.3 per 1,000) compared with non-Hispanic black children (13.1 per 1,000), and Hispanic (10.2 per 1,000) children aged 8 years. Estimated prevalence varied widely among the 11 ADDM Network sites, ranging from 8.2 per 1,000 children aged 8 years (in the area of the Maryland site where only health care records were reviewed) to 24.6 per 1,000 children aged 8 years (in New Jersey, where both education and health care records were reviewed). Estimated prevalence was higher in surveillance sites where education records and health records were reviewed compared with sites where health records only were reviewed (17.1 per 1,000 and 10.4 per 1,000 children aged 8 years, respectively; p<0.05). Among children identified with ASD by the ADDM Network, 82% had a previous ASD diagnosis or educational classification; this did not vary by sex or between non-Hispanic white and non-Hispanic black children. A lower percentage of Hispanic children (78%) had a previous ASD diagnosis or classification compared with non-Hispanic white children (82%) and with non-Hispanic black children (84%). The median age at earliest known comprehensive evaluation was 40 months, and 43% of children had received an earliest known comprehensive evaluation by age 36 months. The percentage of children with an earliest known comprehensive evaluation by age 36 months was similar for boys and girls, but was higher for non-Hispanic white children (45%) compared with non-Hispanic black children (40%) and Hispanic children (39%). INTERPRETATION: Overall estimated ASD prevalence was 14.5 per 1,000 children aged 8 years in the ADDM Network sites in 2012. The higher estimated prevalence among sites that reviewed both education and health records suggests the role of special education systems in providing comprehensive evaluations and services to children with developmental disabilities. Disparities by race/ethnicity in estimated ASD prevalence, particularly for Hispanic children, as well as disparities in the age of earliest comprehensive evaluation and presence of a previous ASD diagnosis or classification, suggest that access to treatment and services might be lacking or delayed for some children. PUBLIC HEALTH ACTION: The ADDM Network will continue to monitor the prevalence and characteristics of ASD among children aged 8 years living in selected sites across the United States. Recommendations from the ADDM Network include enhancing strategies to 1) lower the age of first evaluation of ASD by community providers in accordance with the Healthy People 2020 goal that children with ASD are evaluated by age 36 months and begin receiving community-based support and services by age 48 months; 2) reduce disparities by race/ethnicity in identified ASD prevalence, the age of first comprehensive evaluation, and presence of a previous ASD diagnosis or classification; and 3) assess the effect on ASD prevalence of the revised ASD diagnostic criteria published in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

BACKGROUND: The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS: We randomly assigned, in a double-blind 1:1:1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS: The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P=0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P=0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P<0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS: In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).

BACKGROUND: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk. METHODS: In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up. RESULTS: Of six primary variables, two correlated significantly with infection risk: the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of HIV-1 envelope proteins (Env) correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 per 1-SD increase; P=0.02; q=0.08), and the binding of plasma IgA antibodies to Env correlated directly with the rate of infection (estimated odds ratio, 1.54 per 1-SD increase; P=0.03; q=0.08). Neither low levels of V1V2 antibodies nor high levels of Env-specific IgA antibodies were associated with higher rates of infection than were found in the placebo group. Secondary analyses suggested that Env-specific IgA antibodies may mitigate the effects of potentially protective antibodies. CONCLUSIONS: This immune-correlates study generated the hypotheses that V1V2 antibodies may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have mitigated the effects of protective antibodies. Vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.

PROBLEM/CONDITION: Autism spectrum disorder (ASD). PERIOD COVERED: 2018. DESCRIPTION OF SYSTEM: The Autism and Developmental Disabilities Monitoring (ADDM) Network conducts active surveillance of ASD. This report focuses on the prevalence and characteristics of ASD among children aged 8 years in 2018 whose parents or guardians lived in 11 ADDM Network sites in the United States (Arizona, Arkansas, California, Georgia, Maryland, Minnesota, Missouri, New Jersey, Tennessee, Utah, and Wisconsin). To ascertain ASD among children aged 8 years, ADDM Network staff review and abstract developmental evaluations and records from community medical and educational service providers. In 2018, children met the case definition if their records documented 1) an ASD diagnostic statement in an evaluation (diagnosis), 2) a special education classification of ASD (eligibility), or 3) an ASD International Classification of Diseases (ICD) code. RESULTS: For 2018, across all 11 ADDM sites, ASD prevalence per 1,000 children aged 8 years ranged from 16.5 in Missouri to 38.9 in California. The overall ASD prevalence was 23.0 per 1,000 (one in 44) children aged 8 years, and ASD was 4.2 times as prevalent among boys as among girls. Overall ASD prevalence was similar across racial and ethnic groups, except American Indian/Alaska Native children had higher ASD prevalence than non-Hispanic White (White) children (29.0 versus 21.2 per 1,000 children aged 8 years). At multiple sites, Hispanic children had lower ASD prevalence than White children (Arizona, Arkansas, Georgia, and Utah), and non-Hispanic Black (Black) children (Georgia and Minnesota). The associations between ASD prevalence and neighborhood-level median household income varied by site. Among the 5,058 children who met the ASD case definition, 75.8% had a diagnostic statement of ASD in an evaluation, 18.8% had an ASD special education classification or eligibility and no ASD diagnostic statement, and 5.4% had an ASD ICD code only. ASD prevalence per 1,000 children aged 8 years that was based exclusively on documented ASD diagnostic statements was 17.4 overall (range: 11.2 in Maryland to 29.9 in California). The median age of earliest known ASD diagnosis ranged from 36 months in California to 63 months in Minnesota. Among the 3,007 children with ASD and data on cognitive ability, 35.2% were classified as having an intelligence quotient (IQ) score ≤70. The percentages of children with ASD with IQ scores ≤70 were 49.8%, 33.1%, and 29.7% among Black, Hispanic, and White children, respectively. Overall, children with ASD and IQ scores ≤70 had earlier median ages of ASD diagnosis than children with ASD and IQ scores >70 (44 versus 53 months). INTERPRETATION: In 2018, one in 44 children aged 8 years was estimated to have ASD, and prevalence and median age of identification varied widely across sites. Whereas overall ASD prevalence was similar by race and ethnicity, at certain sites Hispanic children were less likely to be identified as having ASD than White or Black children. The higher proportion of Black children compared with White and Hispanic children classified as having intellectual disability was consistent with previous findings. PUBLIC HEALTH ACTION: The variability in ASD prevalence and community ASD identification practices among children with different racial, ethnic, and geographical characteristics highlights the importance of research into the causes of that variability and strategies to provide equitable access to developmental evaluations and services. These findings also underscore the need for enhanced infrastructure for diagnostic, treatment, and support services to meet the needs of all children.

Table: of ContentsA. EXECUTIVE SUMMARY Updated US consensus guidelines for management of cervical screening abnormalities are needed to accommodate the 3 available cervical screening strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cervical cytology, and cervical cytology alone. New data indicate that a patient's risk of developing cervical precancer or cancer can be estimated using current screening test results and previous screening test and biopsy results, while considering personal factors such as age and immunosuppression. Routine screening applies only to asymptomatic individuals who do not require surveillance for prior abnormal screening results. The 2012 consensus guidelines were the first to be based on the principle of equal management for equal risk, specifically, the risk of a patient developing cervical cancer, estimated by the surrogate end point of the 5-year risk of cervical intraepithelial neoplasia (CIN) grade 3 (CIN 3) or more severe diagnoses (CIN 3+), regardless of which test combinations yielded this risk level. Introduction of risk-based guidelines in 2012 was a conceptual breakthrough, but the recommendations retained a continued reliance on complicated algorithms and insufficiently incorporated screening history. With a more nuanced understanding of how previous results affect risk, and more variables to consider, the 2019 guidelines further align management recommendations with current understanding of HPV natural history and cervical carcinogenesis. More frequent surveillance, colposcopy, and treatment are recommended for patients at progressively higher risk, whereas those at lower risk can defer colposcopy, undergo follow-up at longer surveillance intervals, and, when at sufficiently low risk, return to routine screening. Clearly defined risk thresholds to guide management are designed to continue functioning appropriately when population-level prevalence of CIN 3+ decreases because of HPV vaccination and also as new screening and triage tests are introduced. The revised guidelines provide a framework for incorporating new data and technologies as ongoing incremental recommendation revisions, minimizing the time needed to implement changes that are beneficial to patient care. B. INTRODUCTION This is the fourth American Society of Colposcopy and Cervical Pathology (ASCCP)-sponsored consensus guidelines for management of cervical cancer screening abnormalities, after the original consensus conferences in 20011 and subsequent updates in 20062 and 2012.3 An interim guidance publication providing management recommendations for primary HPV screening was released in 2015.4This document updates and replaces all previous guidance. The key difference between 2019 guidelines and previous versions is the change from primarily test results–based algorithms (e.g., “Colposcopy is recommended for patients with HPV-positive atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL],” etc.) to primarily “risk-based” guidelines (e.g., “Colposcopy is recommended for any combination of history and current test results yielding a 4.0% or of CIN for of risk for combinations of current screening test results and screening history from a of more patients for more a at of risk are in the by The of risk to and in data from screening and those with abnormalities, can be by risk using to in and to a recommended to routine screening, surveillance with testing at or intervals, colposcopy, or of the be and of the abnormalities are using risk in and abnormalities are the consensus recommendations in are based on risk, not results. of colposcopy, or surveillance be based on a patient's risk of CIN 3+ by a combination of current results and history The current test results management recommendations on the history of test results. Colposcopy can be for HPV testing or cotesting at is recommended for patients with screening abnormalities HPV with low risk of CIN 3+ (e.g., low-grade abnormalities after a screening HPV test or 3) for treatment is treatment treatment was for patients with cytology in the 2012 this guidance is patients or defined as treatment biopsy CIN is when the risk of CIN 3+ is and is for those with between and treatment is for patients or with squamous intraepithelial lesion cytology and testing for HPV HPV and or patients with HPV-positive cytology regardless of HPV be when considering for patients with the of treatment on treatment is to treatment for (CIN or CIN 3) in the is recommended for in is to treatment for CIN based on recommendations for CIN or CIN 3 and (CIN primary HPV screening regardless of triage testing from the (e.g., testing from the is recommended because the those cytology for HPV or the risk for CIN 3 and cancer, (e.g., with is when cytology results are HPV or testing is and testing of the is not the patient to surveillance with HPV testing or cotesting at for at is recommended after treatment and management of CIN CIN or surveillance at is for as as the patient's and to be are not by The 2012 guidelines recommended return to 5-year screening and not when screening New that risk for at with that patients return to risk with 5-year with cytology is only testing with HPV or cotesting is not is HPV testing for of precancer and is recommended more is recommended at when HPV testing or cotesting is recommended is recommended when are recommended for HPV or that are and for screening be for management to in the all HPV testing in this document to testing for HPV all management HPV and HPV tests for primary screening only be as a with cytology, data are available to of tests in The of data to a recommendation the patient's age and current test results, as that previous screening history is not of management guidance be is available on test results the and previous precancer treatment the results and history are designed to the patient's risk from data are available for the abnormal screening test results with abnormal screening test results with of a HPV test or surveillance of previous abnormal screening test results that not require (e.g., follow-up after HPV-positive cytology results, and follow-up surveillance tests after or after treatment or abnormalities (e.g., CIN The that HPV is for developing precancer and cancer as CIN which diagnoses of CIN and the 2019 data indicate that when a new abnormal screening test a HPV test or the the estimated risk of CIN 3+ is by cytology 3 of a new abnormal screening not a in The 2019 guidelines also that a to (e.g., using the or the Colposcopy low-grade or a patient's estimated risk of in the This patients with HPV-positive or at follow-up after a or low-grade to return for HPV or cotesting in more return to incorporating a patient's history of previous HPV tests and results and treatment of CIN 3+ while for patients with new HPV who are at lower are based on The first are new for whereas the are from the 2012 the 2012 guidelines are to management recommendations only when new management that management guidelines only to patients with current or previous abnormal screening test screening guidelines for individuals in the that are not for a screening are New 2019 testing is the for risk The testing is this document and to of primary HPV testing or HPV testing in with cervical cytology of HPV HPV and the of a patient's risk of CIN cytology from and can be when risk, lower and lower with HPV testing for risk The results of HPV tests or in with cytology are to guide recommendations that of follow-up and of for results. risk the 2019 management guidelines are based on HPV risk-based management is with of current results and history. patient's risk of or developing CIN 3+ is estimated based on current and previous results, as as history of previous precancer recommendations thresholds of of routine screening, or surveillance, colposcopy, or treatment to a risk a of risk for CIN The lower of risk the at which the management recommendation The for risk were the consensus were estimated for all combination of current results and history for which data were available at can be and of the can be using updates to new test as are and to for as more patients who HPV vaccination screening The of cervical cancer is with new technologies on the of new technologies are and risk from HPV vaccination is as and individuals age screening to consensus which are and not with the of the The 2019 guidelines a framework that of new technologies and consensus that new and be to patient care. for management the 2019 consensus in but as new tests available and more data the test combinations to thresholds at the 2019 consensus HPV vaccination in the or were low to incorporating HPV vaccination the 2019 management this is to change in the as more who lower CIN 3+ risk, the age of and data the of vaccination on the CIN 3+ risk with abnormal test The framework as data available and are new data can be while the This is to with guidance in the Colposcopy Colposcopy with biopsy the primary of patients are after a CIN grade or higher (CIN is not of CIN at is that be of all to at those at risk, defined as cytology, of HPV and a or and a are not recommended and patients with a can be that CIN is not the Colposcopy the for when the is but any of or is 2012 primary of screening and management is cancer and treatment of cervical population-level indicate that and from cervical cancer as and treatment of cervical abnormalities defined as CIN and treatment of the grade of (CIN the for previous and the primary of the 2019 management a of the of this in the is of cervical cancer to and patient's risk of or developing CIN 3+ is estimated based on current and previous results, as as history of previous precancer recommendations are by risk of routine screening, or surveillance, colposcopy, or treatment to a risk risk of risk for CIN are defined by that were the consensus to all individuals with a to and with a individuals who were in individuals of and and to be not the primary of the 2019 management recommendations are also for patients who with of the and who a previous of CIN CIN CIN of the was for precancer treatment or management for equal and current test results are to a patient's current and risk of CIN are regardless of the combination of to the and the cancer with and all cervical is not to cervical cancer can The 2019 guidelines are designed to cervical cancer and from and by patients to current and of CIN patients require follow-up to of CIN whereas patients require tests and to asymptomatic patients that require management of abnormal cervical screening test results. with such as abnormal or or a require testing as this be a of This cervical cytology, colposcopy, and or all and is in those which are not by the 2019 are for in the management in with follow-up of colposcopy, or of the between cancer risk, and and The and a of in to the of this with the previous and 2012 risk data and for the consensus The the consensus to and the in the were and to patient and to cervical cancer screening and management of abnormal results of the and, for to consensus from the in that were previous consensus test (e.g., and the for the 2019 guidelines were with the of consensus The treatment which risk of CIN 3+ treatment as as The the for The surveillance a of at recommended for routine screening with HPV primary testing or cotesting and also when patients return to routine screening. surveillance those with abnormal screening results not (e.g., HPV-positive for or after with low-grade results, or after treatment for The risk factors that change a patient's estimated risk or on and immunosuppression. The to management and continue to as the 2019 guidelines are The new technologies and technologies to The and for to and the the guidelines and the were of to of and of patient from 2019 to data and guidelines for The consensus was by a by the and was by a of and the guidelines a the guidelines a and of patient and a consensus to and a the consensus in of CIN 3+ as for the management CIN 3+ as the surrogate for cancer The of CIN 3+ as in guidelines CIN and the of cervical cancer that are in screening management guidelines CIN 3+ risk at the time point for the for and treatment of CIN whereas surveillance recommendations 5-year was as of cancer because cancer is in the and risk is by that are in screening at first screening, of or not by screening, or CIN 3+ was of CIN because is a more the HPV in CIN 3+ more that of cervical the of in CIN and CIN in the of The of CIN 3+ as CIN of to cancer with HPV and and those in patients higher cancer and those in for cervical are in in the The and the a for of squamous to the for cervical the CIN is and data to this of guidelines on CIN is of the is but not to CIN to guidelines on a data results of cytology, HPV colposcopy, and follow-up from which cotesting as in The data continue to be the data in the for risk of combinations of HPV testing and the 2019 were to that results are to patients of and were using screening and follow-up data from a HPV and the for and and Cervical a that and The in of abnormal screening results and the prevalence of CIN the that the of CIN 3+ for the combination of current results and screening history were in that the risk for the of CIN 3+ with screening test combinations the of patients from data the higher or lower of CIN 3+ to factors to screening and HPV patients with test results and screening history combinations CIN 3+ risk, regardless of or of of how of CIN 3+ were for the combinations of test results, of tests are in the for combination of and current test results, the risk of CIN 3+ was estimated using which of of CIN 3+ at the time of the current testing using a and CIN 3+ at subsequent testing using a are designed to and in this that are only available for patients to that in the of screening or abnormal screening tests that were not for not be in this that the CIN 3+ is at but the time of of CIN 3+ be as is asymptomatic and between testing are designed to provide risk the data a (e.g., of to combination of current test results and screening history recommended management was by first and 5-year risk of CIN The estimated risk was with the to management the principle of management for equal HPV-positive and cytology of CIN 3+ and are combinations of test results, patients CIN 3+ to risk with a combination of previous and consensus were to the and of were using the that for previous consensus guidelines of were to be to a of and by the new technologies using the to risk for the and risk from the point are defined as of the risk for the recommended management on the of the and 5-year risk (e.g., and surveillance from and risk from are recommendations a management because the risk of a (e.g., biopsy in primary data previous guidelines or consensus were 3 to a recommendations are of guidelines from which were not considering from of and primary data from the the and of this and recommendations based on of data and a of and the This the from to risk-based the primary on which management recommendations are based and the in which are abnormal screening results and subsequent management the recommendations are based on estimated and by data from can the 2019 guidelines to patients the in or by using or designed to of the available at a to recommendations for management is based on factors risk recommendations are based on and to risk This how patient risk is a current results and history the CIN 3+ risk is this risk is or management or treatment is the risk is the 5-year CIN 3+ risk is to patients return in or The 5-year return the risk for a patient after a screening test using HPV testing or cotesting in the for in is recommended by screening with at or this are recommended to routine screening at 5-year with testing The return the risk for a patient after a cervical cytology in the for in 3 is recommended by screening with at or this but the 5-year are recommended to testing in 3 return is recommended for patients with the but the for The the risk for a patient after HPV-positive or screening in the for is recommended in the 2012 with at or this but the treatment are recommended to The treatment or the risk for a patient after HPV-positive atypical squamous cells cytology screening in the with at or this but the treatment are recommended to from to between with and biopsy or treatment treatment is defined as treatment The treatment the risk for a patient after HPV cytology screening in the is that patients with at or this treatment are or the of treatment on that cancer patients with (CIN who are recommended to and testing at to of Introduction is defined as follow-up testing at a that recommended for routine screening with HPV primary testing or cotesting is recommended for patients risk of CIN 3+ based on current test results and screening history is higher the risk for the screening but lower the risk at which is and which are as as after a abnormal surveillance at of to the 5-year risk of CIN 3+ as the estimated risk when surveillance are defined in and in thresholds are based on the principle of equal management for equal and were designed to current screening and surveillance which are as a of and the 2012 of and 3 were for surveillance, with return to routine screening at and patients are with intervals, and of not a to change intervals, are that for in patients (e.g., with and testing at is patients estimated 5-year CIN 3+ risk of based on history and current test results, return to routine screening at 5-year using testing is recommended the principle of equal management for equal risk, this to the 5-year CIN 3+ risk after screening testing or in the in for guidelines a 5-year 5-year CIN 3+ in the after a HPV test and are and that cytology is recommended at 5-year patients estimated 5-year CIN 3+ risk of or but based on history and current test results, testing in 3 with testing is recommended the principle of equal management for equal risk, the return to the 5-year CIN 3+ risk after cervical cytology in the for guidelines a 5-year CIN 3+ after a cytology HPV testing from in the to in the New HPV to estimated in the of the and Cervical was for the surveillance is recommended for patients risk between the and 5-year follow-up with the 2012 patients with a low-grade (e.g., HPV-positive or by a with results of CIN in by a follow-up HPV test or the return with previous patients with screening in the of history can return at 3 CIN 3+ risk This how a patient with a low-grade screening be based on risk The screening to risk Colposcopy of CIN a 5-year risk of the return a HPV-positive risk of the patient a abnormal at the is the test is return in 3 is not because risk are not patients estimated risk of CIN 3+ based on history and current results that is the for and the follow-up at testing in with testing is recommended surveillance follow-up for those between the for and with the 2012 consensus follow-up at is recommended after screening tests or with previous screening history and surveillance is also recommended after with of (CIN or by a low-grade as HPV-positive HPV-positive or HPV-positive New data for guidelines that the risk of CIN 3+ is after a HPV primary screening test or or with biopsy of CIN on lower CIN 3+ surveillance, not colposcopy, is recommended for patients with new HPV-positive or results after a HPV test or screening or CIN the a previous cytology not subsequent risk a cytology is not to subsequent management to of Colposcopy patients estimated risk of of CIN 3+ of 4.0% or based on history and current results, to is recommended The were to the for to recommended by the for the was based on the risk of CIN 3+ to the of a the be to 2012 recommendations that are as of and The consensus were the first to the patients with and HPV-positive to This recommendation in and The and that risk (CIN 3+ patients to from to data were and was that CIN 3+ risk in 3 test results as cytology atypical or low-grade results or HPV-positive cytology with previous screening history and HPV-positive cytology at 4.0% and combinations for which not cytology, cytology, and cytology with previous screening The of a CIN 3+ risk was a of and in a with screening to of HPV-positive patients with or cytology, but not the of patients with HPV-positive the 4.0% for colposcopy, the CIN 3+ risk were with those from with more in the New HPV and Cervical and the The The 4.0% risk for patients with at previous test because surveillance is recommended for low-grade abnormalities or in patients screening was a HPV test or a routine screening This the CIN 3+ risk to to a recommendation of surveillance of of the 4.0% the of patients for of screening from estimated using the 2012 to using the 2019 to the 4.0% results with cancer risk higher CIN 3+ risk, are in to of The primary of treatment is cancer or of (CIN to the of the only of CIN the risk of developing cancer was as as for not be estimated at because of of treatment is recommended as as after the of a the CIN 3+ risk was when the treatment CIN The guidelines CIN and CIN 3 as with previous the for treatment or CIN in and considering treatment with a with patients the and can be in those at risk of CIN for treatment and personal and The age of or for treatment was as of and to low cancer and of of in this age patients or with estimated risk of CIN 3+ of or based on history and current results, treatment using previous biopsy is but with biopsy is the 2012 treatment biopsy was management for with cytology treatment are with CIN 3+ in to of The data HPV-positive cytology of CIN 3+ and CIN of and the treatment is cytology that is HPV CIN 3+ of CIN of and cancer of the and Cervical with HPV-positive cytology of who were defined as screening in CIN 3+ risk of and CIN of risk not on the for that the patients for CIN 3+ a low of patients or with estimated risk of CIN 3+ or and based on history and current results, treatment using previous biopsy or with and biopsy are The 2012 guidelines treatment patients who cytology of HPV the data the to patients with the results and CIN 3+ HPV-positive HPV-positive and HPV-positive this patients undergo for CIN 3+ to with abnormal cervical cancer screening results management management of abnormal screening test return for surveillance of a previous abnormal that not to (e.g., with of to continue surveillance or to of the biopsy results with of to or surveillance test results at the return for surveillance after a biopsy CIN and follow-up after treatment of or are based on of and CIN 3+ diagnoses in of current and results. of the by which patients are of the risk and recommendations based on the are in the by The is to the of risk which are available of patients with a combination of results and personal of the available risk of is in to of the 2019 guidelines management of patients by the consensus also that to results and of on the of a for of of the is to to the guidance by the be for as recommended by the guidelines when the and the of the of is with CIN or CIN is a risk of cervical results when is a CIN on not be to (CIN and management is recommended to a by CIN or CIN to the by the guidelines This CIN can (e.g., to of CIN in patients for management is is also for surveillance and of cervical precancer that on CIN and CIN 3 end is for to diagnoses of (CIN from (CIN 3) that are with the end for current consensus recommendations were on the of a for of squamous of the by the of American and the The of the guidelines a that and and recommendations for the of to of is a of HPV and and can guidelines are based on CIN 3 end the of a cervical are data to risk with end that CIN and CIN 3 the is and that of cervical and Updated of HPV primary HPV screening is of triage test (e.g., for all HPV tests regardless of is tests for HPV primary HPV screening test results are HPV or HPV and triage testing from the is not for testing is for HPV or HPV is and triage testing is not the colposcopy, of triage test (e.g., at the is recommended The US the HPV test in and the HPV in for primary HPV testing for screening for patients or tests and are for HPV of primary HPV screening in the as is more screening with cytology and to and with lower screening with and HPV test results the risk of CIN 3 and are recommended for all test results (e.g., with biopsy for and low-grade cytology and treatment for cytology that is for HPV This replaces interim guidance for the management of a for HPV primary screening, which recommended to for HPV test results for HPV HPV and of cytology for results to HPV The risk of in patients with HPV and cytology the treatment of patients be the for treatment biopsy treatment is only cytology is cytology is recommended for all HPV-positive primary screening results, regardless of HPV testing from the as the HPV test is not patients to this of triage test (e.g., is recommended at the time of to provide further for risk-based management (e.g., HPV cytology is treatment be CIN is not on a test with (e.g., cytology when is as with a test with HPV more risk-based management of on HPV in HPV be for management to for screening, are data to of the HPV in the for in screening and of for but are for and HPV for screening be to when HPV test for be in management in the of are data to of the (e.g., as in and of HPV as as HPV HPV are for testing with cytology to as whereas a of HPV also for primary HPV testing of as or patients of all with all of and when atypical cells are is recommended regardless of HPV test is recommended at in management in triage by HPV testing is not and triage by cytology is is recommended in with and in patients or with all of and is also recommended for patients at risk of neoplasia based on (e.g., abnormal or patients with atypical cells to and is with at the time of was and is with is recommended This the of on cervical patients with cytology not or atypical cells not in (CIN or is not cotesting at and is are cotesting at 3 is any test is is recommended CIN or CIN 3 but lesion is for patients with cytology atypical or cells not management be to the 2019 guidelines for the lesion patients with atypical or cells or cytology, is not a is The in this provide with the is This follow-up management that after the in 3 cells on cytology is a HPV test results, when for HPV can be of higher risk of CIN is recommended for all patients regardless of HPV is and between are because of of the for of cells can be with and as as of the of the and are also in who test HPV the or cytology is of or this are recommended when or not results are with a of in to CIN in and cancer in to the HPV-positive CIN 3+ risk of and CIN 3+ risk of with results of HPV-positive neoplasia or CIN 3+ risk of whereas HPV-positive CIN 3+ of cancer is in patients risk the prevalence of cancer is the of when patients with cytology and or a HPV test screening or primary HPV in to is recommended using HPV testing is not recommended cytology, treatment to or when a is is patients and who are and cytology and a HPV test cytology in to or is a HPV test with is for HPV or HPV for is recommended This the in management of that to HPV testing and HPV testing is for HPV and but for HPV was from 2012 to and was to change cotesting is a HPV test in the of cytology a HPV test from the as the be for testing when the cytology is for the HPV in the of not which is of that testing is not recommended for to after a HPV results on HPV tests that are not for primary cervical cancer screening not be in the of cytology a HPV from a with on cytology not be as primary HPV test and be on patients to with screening cytology and

Silent information regulator (Sir)2, a class III histone deacetylase, mediates lifespan extension in model organisms and prevents apoptosis in mammalian cells. However, beneficial functions of Sir2 remain to be shown in mammals in vivo at the organ level, such as in the heart. We addressed this issue by using transgenic mice with heart-specific overexpression of Sirt1, a mammalian homolog of Sir2. Sirt1 was significantly upregulated (4- to 8-fold) in response to pressure overload and oxidative stress in nontransgenic adult mouse hearts. Low (2.5-fold) to moderate (7.5-fold) overexpression of Sirt1 in transgenic mouse hearts attenuated age-dependent increases in cardiac hypertrophy, apoptosis/fibrosis, cardiac dysfunction, and expression of senescence markers. In contrast, a high level (12.5-fold) of Sirt1 increased apoptosis and hypertrophy and decreased cardiac function, thereby stimulating the development of cardiomyopathy. Moderate overexpression of Sirt1 protected the heart from oxidative stress induced by paraquat, with increased expression of antioxidants, such as catalase, through forkhead box O (FoxO)-dependent mechanisms, whereas high levels of Sirt1 increased oxidative stress in the heart at baseline. Thus, mild to moderate expression of Sirt1 retards aging of the heart, whereas a high dose of Sirt1 induces cardiomyopathy. Furthermore, although high levels of Sirt1 increase oxidative stress, moderate expression of Sirt1 induces resistance to oxidative stress and apoptosis. These results suggest that Sirt1 could retard aging and confer stress resistance to the heart in vivo, but these beneficial effects can be observed only at low to moderate doses (up to 7.5-fold) of Sirt1.

OBJECTIVE: To quantify the protective efficacy of influenza vaccine in elderly persons. DATA SOURCES: A MEDLINE search was done using the index terms influenza vaccine, vaccine efficacy, elderly, mortality, hospitalized, and pneumonia. Appropriate references in the initially selected articles were also reviewed. STUDY SELECTION: Only cohort observational studies with mortality assessment were included in the meta-analysis. In addition, 3 recent case-control studies, 2 cost-effectiveness studies, and 1 randomized, double-blind, placebo-controlled trial were reviewed. DATA EXTRACTION: Vaccine and epidemic virus strains, age and sex of patients, severity of illness, patient status, and study design were recorded. Upper respiratory illness, hospitalization, pneumonia, and mortality were used as outcome measures. DATA SYNTHESIS: In a meta-analysis of 20 cohort studies, the pooled estimates of vaccine efficacy (1-odds ratio) were 56% (95% Cl, 39% to 68%) for preventing respiratory illness, 53% (Cl, 35% to 66%) for preventing pneumonia, 50% (Cl, 28% to 65%) for preventing hospitalization, and 68% (Cl, 56% to 76%) for preventing death. Vaccine efficacy in the case-control studies ranged from 32% to 45% for preventing hospitalization for pneumonia, from 31% to 65% for preventing hospital deaths from pneumonia and influenza, from 43% to 50% for preventing hospital deaths from all respiratory conditions, and from 27% to 30% for preventing deaths from all causes. The randomized, double-blind, placebo-controlled trial showed a 50% or greater reduction in influenza-related illness. Recent cost-effectiveness studies confirm the efficacy of influenza vaccine in reducing influenza-related morbidity and mortality and show that vaccine provides important cost savings per year per vaccinated person. CONCLUSION: Despite the paucity of randomized trials, many studies confirm that influenza vaccine reduces the risks for pneumonia, hospitalization, and death in elderly persons during an influenza epidemic if the vaccine strain is identical or similar to the epidemic strain. Influenza immunization is an indispensable part of the care of persons 65 years of age and older. Annual vaccine administration requires the attention of all physicians and public health organizations.

CONTEXT: Few prospective longitudinal studies have examined the relationship between abuse or neglect in childhood and depression in adulthood. OBJECTIVE: To determine whether abused and neglected children were at elevated risk of major depressive disorder (MDD) and psychiatric comorbidity, compared with matched control subjects, when followed up into young adulthood. DESIGN: Prospective cohort design study. SETTING: Midwestern metropolitan county area. PARTICIPANTS: Children with substantiated cases of physical and sexual abuse and neglect (before the age of 11 years) from January 1, 1967, to December 31, 1971 (n = 676) were matched based on age, race, sex, and approximate family social class with a group of non-abused and non-neglected children (n = 520) and followed up into young adulthood (mean age, 28.7 years). MAIN OUTCOME MEASURES: Between October 20, 1989, and December 22, 1995, 2-hour in-person interviews were conducted, using the National Institute of Mental Health Diagnostic Interview Schedule, Version III Revised, to determine DSM-III-R MDD and other psychiatric diagnoses. RESULTS: Child abuse and neglect were associated with an increased risk for current MDD (odds ratio [OR], 1.51; 95% confidence interval [CI], 1.06-2.14; P< or=.05) in young adulthood. Children who were physically abused (OR, 1.59; 95% CI, 1.00-2.52; P< or =.05) or experienced multiple types of abuse (OR, 1.75; 95% CI, 1.01-3.02; P< or =.05) were at increased risk of lifetime MDD, whereas neglect increased risk for current MDD (OR, 1.59; 95% CI, 1.10-2.29; P<.01). Childhood sexual abuse was not associated with elevated risk of MDD. Kaplan-Meier age-of-onset curves (log-rank statistic, 4.03; df = 1; P=.04) showed earlier onset of MDD for abused and neglected children compared with controls. Among those with MDD, comorbidity was higher for abused and neglected individuals than for controls. CONCLUSION: These results support the need for clinicians to increase efforts to detect and treat depression in physically abused and neglected children.